Table 4 Reason for Sertindole Discontinuation during Study Follow-up (682 patients), with type of previously taken treatment
From: The Sertindole Safety Survey: A retrospective analysis under a named patient use programme in Europe
Total N (%) | ||
|---|---|---|
Reason for Stopping | Beforea | Afterb |
Sertindole suspension and Named Patient Use restrictions | 176 (35.3%) | 49 (26.8%) |
Typical antipsychotic(s)c | 50 (25.1%) | 28 (31.5%) |
At least one atypical antipsychoticd | 49 (31.6%) | 15 (20.8%) |
Patient desire to stop | 127 (25.5%) | 50 (27.3%) |
Typical antipsychotic(s)c | 71 (35.7%) | 26 (29.2%) |
At least one atypical antipsychoticd | 39 (25.2%) | 18 (25.0%) |
Lack of efficacy | 64 (12.8%) | 39 (21.3%) |
Typical antipsychotic(s)c | 28 (14.1%) | 17 (19.1%) |
At least one atypical antipsychoticd | 23 (14.8%) | 19 (26.4%) |
Adverse Event(s) | 58 (11.6%) | 19 (10.4%) |
Typical antipsychotic(s)c | 26 (13.1%) | 10 (11.2%) |
At least one atypical antipsychoticd | 20 (12.9%) | 9 (12.5%) |
Other reasons | 74 (14.8%) | 26 (14.2%) |
Typical antipsychotic(s)c | 24 (12.1%) | 8 (9.0%) 11 |
At least one atypical antipsychoticd | 24 (15.5%) | (15.3%) |
Total | 499 (100.0%) | 183 (100.0%) |